Latest News from Health Sites - November 2017

Pradaxa dabigatran etexilate 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RELY Results of the ENGAGE AFTIMI 48 trial published for edoxaban vs. warfarin do

Pradaxa dabigatran etexilate 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RELY Results of the ENGAGE AFTIMI 48 trial published for edoxaban vs. warfarin do
Boehringer Ingelheim Corporate News via MedWorm Static